ES2562925T3 - Sistema de administración de fármaco gastrorretentivo de zaleplón - Google Patents
Sistema de administración de fármaco gastrorretentivo de zaleplón Download PDFInfo
- Publication number
- ES2562925T3 ES2562925T3 ES09830077.5T ES09830077T ES2562925T3 ES 2562925 T3 ES2562925 T3 ES 2562925T3 ES 09830077 T ES09830077 T ES 09830077T ES 2562925 T3 ES2562925 T3 ES 2562925T3
- Authority
- ES
- Spain
- Prior art keywords
- zaleplon
- grdf
- gastro
- polymer
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001647 drug administration Methods 0.000 title 1
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 abstract description 27
- 229960004010 zaleplon Drugs 0.000 abstract description 26
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract description 17
- 239000002775 capsule Substances 0.000 abstract description 8
- 210000002784 stomach Anatomy 0.000 abstract description 5
- 238000013270 controlled release Methods 0.000 abstract description 4
- 210000004051 gastric juice Anatomy 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 239000010410 layer Substances 0.000 description 40
- 229920000642 polymer Polymers 0.000 description 18
- 239000000203 mixture Substances 0.000 description 14
- 230000002496 gastric effect Effects 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 230000001575 pathological effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000004014 plasticizer Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229920003139 Eudragit® L 100 Polymers 0.000 description 4
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229940061368 sonata Drugs 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 229920003141 Eudragit® S 100 Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- WCHSQACWYIQTKL-XPWFQUROSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 WCHSQACWYIQTKL-XPWFQUROSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- UIERETOOQGIECD-UHFFFAOYSA-N Angelic acid Natural products CC=C(C)C(O)=O UIERETOOQGIECD-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920003119 EUDRAGIT E PO Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000989 food dye Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid Chemical compound C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12005108P | 2008-12-04 | 2008-12-04 | |
| US120051P | 2008-12-04 | ||
| PCT/IB2009/007731 WO2010064139A2 (en) | 2008-12-04 | 2009-10-19 | Zaleplon gastroretentive drug delivery system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2562925T3 true ES2562925T3 (es) | 2016-03-09 |
Family
ID=42232930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09830077.5T Active ES2562925T3 (es) | 2008-12-04 | 2009-10-19 | Sistema de administración de fármaco gastrorretentivo de zaleplón |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9693981B2 (enExample) |
| EP (1) | EP2378883B1 (enExample) |
| JP (2) | JP2012510987A (enExample) |
| KR (1) | KR20110116004A (enExample) |
| CN (1) | CN102300463B (enExample) |
| CA (1) | CA2745741A1 (enExample) |
| ES (1) | ES2562925T3 (enExample) |
| IL (1) | IL213376A (enExample) |
| PL (1) | PL2378883T3 (enExample) |
| WO (2) | WO2010064100A1 (enExample) |
| ZA (1) | ZA201104620B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2606395T3 (es) | 2008-04-18 | 2017-03-23 | Intec Pharma Ltd. | Administración de fármacos gastrorretentivos para carbidopa/levodopa |
| UA108211C2 (uk) * | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
| US20130078290A1 (en) * | 2010-06-01 | 2013-03-28 | Rubicon Research Private Limited | Gastroretentive Dosage Forms Of GABA Analogs |
| US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| ES2665569T3 (es) * | 2011-03-01 | 2018-04-26 | Pharnext | Tratamiento de la isquemia cerebral |
| US9180108B2 (en) | 2011-10-27 | 2015-11-10 | Medtronic, Inc. | Baclofen formulations and methods for making same |
| US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| US9622997B2 (en) | 2012-06-01 | 2017-04-18 | Lynn Health Science Institute, Inc. | Methods for treating insomnia |
| WO2014039951A1 (en) * | 2012-09-10 | 2014-03-13 | Novartis Ag | Enteral pharmaceutical compositions |
| CN105431144A (zh) | 2013-06-05 | 2016-03-23 | 思康脑侒股份有限公司 | 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合 |
| US9566248B2 (en) | 2013-09-13 | 2017-02-14 | R.P. Scherer Technologies, Llc | Encased-pellet tablets |
| FR3014692B1 (fr) * | 2013-12-18 | 2016-01-29 | Ethypharm Sa | Compositions pharmaceutiques orales a retention gastrique. |
| JP6666858B2 (ja) | 2014-06-11 | 2020-03-18 | マサチューセッツ インスティテュート オブ テクノロジー | 滞留構造体および関連方法 |
| US20170266112A1 (en) | 2014-06-11 | 2017-09-21 | Massachusetts Institute Of Technology | Residence structures and related methods |
| WO2016109412A1 (en) * | 2014-12-29 | 2016-07-07 | Boston Scientific Scimed, Inc. | Compositions, devices and methods for multi-stage release of chemotherapeutics |
| US10172800B2 (en) | 2015-02-20 | 2019-01-08 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form with enhanced pharmacokinetics |
| US10987328B2 (en) | 2015-02-20 | 2021-04-27 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
| EP3258914A1 (en) | 2015-02-20 | 2017-12-27 | Osmotica Kereskedelmi ES Szolgaltato KFT | Controlled release oral dosage form of gaba receptor agonist |
| US10300032B2 (en) | 2015-02-20 | 2019-05-28 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
| CN118975972A (zh) | 2015-10-23 | 2024-11-19 | 林德拉治疗公司 | 用于治疗剂缓释的胃驻留系统及其使用方法 |
| US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
| BR112018011636B1 (pt) | 2015-12-08 | 2024-03-12 | Lyndra Therapeutics, Inc | Sistema de residência gástrico para liberação sustentada de um agente terapêutico |
| CN119925721A (zh) | 2016-05-27 | 2025-05-06 | 林德拉治疗公司 | 用于胃驻留系统的材料结构 |
| EP3481371A1 (en) * | 2016-07-11 | 2019-05-15 | Intec Pharma Ltd. | Oral gastroretentive formulations and uses thereof |
| CN110022861B (zh) | 2016-09-30 | 2024-06-28 | 林德拉治疗公司 | 用于金刚烷类药物缓释的胃驻留系统 |
| CA3060026A1 (en) * | 2017-04-18 | 2018-10-25 | Jayant Jagannath Khandare | Polymer based formulation for release of drugs and bioactives at specific git sites |
| US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
| AU2018279853B2 (en) | 2017-06-09 | 2024-07-04 | Lyndra Therapeutics, Inc. | Gastric residence systems with release rate-modulating films |
| JP7458317B2 (ja) | 2017-10-31 | 2024-03-29 | サムヤン、ホールディングス、コーポレーション | 崩壊が改善された経口用固形製剤組成物及びその製造方法 |
| EP3941445A4 (en) | 2019-03-20 | 2023-08-02 | Lyndra Therapeutics, Inc. | CAPSULES AND CAPSULE COATINGS FOR GASOLINE DOSAGE FORMS |
| EP3941444B1 (en) * | 2019-03-20 | 2025-03-26 | Lyndra Therapeutics, Inc. | Coatings for gastric residence dosage forms |
| US10792262B1 (en) | 2019-07-29 | 2020-10-06 | Saol International Limited | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
| US11654124B2 (en) | 2019-07-29 | 2023-05-23 | Amneal Pharmaceuticals Llc | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
| US20220409539A1 (en) * | 2019-12-30 | 2022-12-29 | Fraunhofer Usa Inc. | Particles for multi-dose delivery |
| US11491125B1 (en) * | 2021-09-29 | 2022-11-08 | Amneal Pharmaceuticals Llc | Baclofen formulations and methods of minimizing patient exposure to metabolite variations |
| CA3248763A1 (en) * | 2022-01-19 | 2023-07-27 | Lyndra Therapeutics Inc | Pharmaceutical forms for gastric retention |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4451260A (en) * | 1982-03-26 | 1984-05-29 | Minnesota Mining And Manufacturing Company | Sustained release oral medicinal delivery device |
| US4767627A (en) | 1985-05-29 | 1988-08-30 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| JPH07179334A (ja) * | 1993-12-22 | 1995-07-18 | Sanei Touka Kk | カプセル及びカプセル剤の製造方法 |
| US5780055A (en) * | 1996-09-06 | 1998-07-14 | University Of Maryland, Baltimore | Cushioning beads and tablet comprising the same capable of forming a suspension |
| US20010055613A1 (en) | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
| EP1064937A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| US6485746B1 (en) * | 2000-08-25 | 2002-11-26 | Neurocrine Biosciences, Inc. | Controlled-release sedative-hypnotic compositions and methods related thereto |
| IL133196A0 (en) * | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
| DE10004790B4 (de) | 2000-02-01 | 2004-09-09 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung |
| CA2452738C (en) | 2001-07-04 | 2011-06-14 | Sun Pharmaceutical Industries Limited | Gastric retention controlled drug delivery system |
| US20080081834A1 (en) * | 2002-07-31 | 2008-04-03 | Lippa Arnold S | Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders |
| US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US20050038042A1 (en) * | 2002-11-15 | 2005-02-17 | Jenet Codd | Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders |
| CA2510465A1 (en) * | 2002-12-18 | 2004-07-08 | Pain Therapeutics | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
| KR100553887B1 (ko) * | 2003-06-24 | 2006-02-24 | 삼성전자주식회사 | 수직 및 수평으로 광시야각을 갖는 영상표시용 스크린 및이를 구비하는 프로젝션 텔레비전 |
| US20050090554A1 (en) * | 2003-09-12 | 2005-04-28 | John Devane | Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists |
| EP1523981A1 (en) | 2003-10-13 | 2005-04-20 | Wyeth | Extended release formulations of venlafaxine |
| EP1686976A2 (en) * | 2003-11-05 | 2006-08-09 | Santarus, Inc. | Combination of proton pump inhibitor and sleep aid |
| EP1535952B1 (en) * | 2003-11-28 | 2013-01-16 | Universite Louis Pasteur | Method for preparing crosslinked polyelectrolyte multilayer films |
| US20050220874A1 (en) * | 2004-04-02 | 2005-10-06 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist |
| JP4756835B2 (ja) * | 2004-07-14 | 2011-08-24 | キヤノン株式会社 | 生化学反応カートリッジ |
| AU2006261893A1 (en) * | 2005-06-23 | 2007-01-04 | Combinatorx, Incorporated | Improved dosage forms for movement disorder treatment |
| CA2634869C (en) * | 2005-12-23 | 2012-03-06 | Cadbury Adams Usa Llc | Compositions providing a sensation substantially similar to that provided by menthol |
| US8298574B2 (en) | 2006-01-18 | 2012-10-30 | Intec Pharma Ltd. | Method and apparatus for forming delivery devices for oral intake of an agent |
| CA2642479C (en) | 2006-02-15 | 2014-08-19 | Intec Pharma Ltd. | A gastro-retentive system for the delivery of macromolecules |
| US8765178B2 (en) * | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
| ES2365574T3 (es) * | 2007-01-11 | 2011-10-07 | Xenoport, Inc. | Formas de dosificación oral para liberación continua de un profármaco de r-baclofeno y procedimientos de tratamiento. |
| EP1970056A1 (en) | 2007-03-15 | 2008-09-17 | Polichem S.A. | Time-specific delayed/pulsatile release dosage forms |
| US20100137442A2 (en) * | 2008-02-01 | 2010-06-03 | Xenoport, Inc. | Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment |
-
2009
- 2009-10-19 PL PL09830077T patent/PL2378883T3/pl unknown
- 2009-10-19 EP EP09830077.5A patent/EP2378883B1/en not_active Not-in-force
- 2009-10-19 ES ES09830077.5T patent/ES2562925T3/es active Active
- 2009-10-19 KR KR1020117014376A patent/KR20110116004A/ko not_active Withdrawn
- 2009-10-19 JP JP2011539117A patent/JP2012510987A/ja active Pending
- 2009-10-19 WO PCT/IB2009/007419 patent/WO2010064100A1/en not_active Ceased
- 2009-10-19 WO PCT/IB2009/007731 patent/WO2010064139A2/en not_active Ceased
- 2009-10-19 CA CA2745741A patent/CA2745741A1/en not_active Abandoned
- 2009-10-19 CN CN200980153943.5A patent/CN102300463B/zh not_active Expired - Fee Related
- 2009-10-19 US US13/132,899 patent/US9693981B2/en not_active Expired - Fee Related
-
2010
- 2010-06-09 US US12/797,441 patent/US20110091542A1/en not_active Abandoned
-
2011
- 2011-06-05 IL IL213376A patent/IL213376A/en not_active IP Right Cessation
- 2011-06-22 ZA ZA2011/04620A patent/ZA201104620B/en unknown
-
2014
- 2014-11-14 JP JP2014231788A patent/JP6104873B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012510987A (ja) | 2012-05-17 |
| WO2010064139A3 (en) | 2010-09-10 |
| US9693981B2 (en) | 2017-07-04 |
| KR20110116004A (ko) | 2011-10-24 |
| US20110091542A1 (en) | 2011-04-21 |
| CN102300463B (zh) | 2015-03-25 |
| PL2378883T3 (pl) | 2016-06-30 |
| JP2015028094A (ja) | 2015-02-12 |
| WO2010064100A1 (en) | 2010-06-10 |
| EP2378883A2 (en) | 2011-10-26 |
| IL213376A0 (en) | 2011-07-31 |
| JP6104873B2 (ja) | 2017-03-29 |
| EP2378883B1 (en) | 2015-12-23 |
| CA2745741A1 (en) | 2010-06-10 |
| US20120021051A1 (en) | 2012-01-26 |
| IL213376A (en) | 2015-06-30 |
| CN102300463A (zh) | 2011-12-28 |
| ZA201104620B (en) | 2012-03-28 |
| EP2378883A4 (en) | 2014-03-05 |
| WO2010064139A2 (en) | 2010-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2562925T3 (es) | Sistema de administración de fármaco gastrorretentivo de zaleplón | |
| Vrettos et al. | Gastroretentive technologies in tandem with controlled-release strategies: A potent answer to oral drug bioavailability and patient compliance implications | |
| Klausner et al. | Expandable gastroretentive dosage forms | |
| Omidian et al. | Recent developments in superporous hydrogels | |
| US20120321706A1 (en) | Novel gastroretentive dosage forms of poorly soluble drugs | |
| JP6325148B2 (ja) | 注意欠陥障害の処置のための方法および組成物 | |
| ES2849873T3 (es) | Administración de fármacos gastrorretentivos de carbidopa/levodopa | |
| Shaha et al. | An overview of a gastro-retentive floating drug delivery system | |
| ES2645930T3 (es) | Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas | |
| US20040052844A1 (en) | Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins | |
| US20060045865A1 (en) | Controlled regional oral delivery | |
| ES2967085T3 (es) | Preparación farmacéutica para administración oral con tasa de disolución controlada, la preparación que comprende gránulos de liberación sostenida que contienen clorhidrato de tamsulosina | |
| ES2958616T3 (es) | Formulaciones farmacéuticas de floroglucinol y trimetilfloroglucinol | |
| ES2901522T3 (es) | Sistemas de suministro de fármacos gastrorretentivos osmóticos autorregulados | |
| Arafat | Approaches to achieve an oral controlled release drug delivery system using polymers: a recent review | |
| US20080089937A1 (en) | Controlled release drug compositions and preparation methods | |
| JP2008540437A (ja) | キニーネを含有する制御放出調合剤 | |
| CA3235311A1 (en) | Erdafitinib formulations and systems for intravesical administration | |
| JP2023509754A (ja) | リオチロニンを含む持続放出組成物 | |
| Krishna et al. | Strategic Approaches and Evaluation of Gastro Retentive Drug Delivery system-A Review | |
| CN100536838C (zh) | 一种盐酸坦洛新控释片制剂及其制备方法 | |
| TR201801650T1 (tr) | Kontrollü salim propi̇veri̇n formülasyonlari | |
| EP4209208A1 (en) | Swallowable, self-expandable drug delivery device and uses thereof | |
| Mali Hanmant et al. | A review on floating and mucoadhesive drug delivery system | |
| ES2868228T3 (es) | Formas de dosificación farmacéuticas que contienen 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1H-1,2,3-triazol-1-il)-1H-pirazol-5-olato de sodio |